In operating theaters across Britain, a collision between technological promise and clinical reality has quietly unfolded. A landmark randomized trial — the largest of its kind — has found that robotic-assisted knee replacement, for all its mechanical precision, offers patients no measurable advantage over conventional surgery in the first year of recovery. The finding does not condemn the machines so much as it reveals a deeper truth: that precision is a tool, not an outcome, and that the art of knowing how to use it wisely has not yet caught up with the engineering that made it possible.